Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Immunomedics Inc (IMMU)

Immunomedics Inc (IMMU)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Immunomedics Inc 300 AMERICAN RD MORRIS PLAINS NJ 07950 USA

P: 973-605-8200

Description:

Immunomedics Inc. is a New Jersey-based biopharmaceutical company focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. They have developed a number of advanced proprietary technologies that allow us to create humanized antibodies that can be used either alone in unlabeled or `naked` form, or conjugated with radioactive isotopes, chemotherapeutics or toxins, in each case to create highly targeted agents. Using these technologies, the company have built a pipeline of therapeutic product candidates that utilize several different mechanisms of action. They have recently licensed its lead product candidate, epratuzumab, to UCB, S.A. for the treatment of all autoimmune disease indications worldwide.

Key Statistics

Overview:

Market Capitalization, $K 20,308,312
Shares Outstanding, K 231,144
Annual Sales, $ 300 K
Annual Net Income, $ -357,190 K
Last Quarter Sales, $ 20,070 K
Last Quarter Net Income, $ -66,470 K
60-Month Beta 2.90
% of Insider Shareholders 12.00%
% of Institutional Shareholders 88.89%
Float, K 203,407
% Float 88.00%

Growth:

1-Year Return 446.05%
3-Year Return 651.58%
5-Year Return 2,838.46%
5-Year Revenue Growth -94.69%
5-Year Earnings Growth -534.48%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.30 on 08/05/20
Next Earnings Date 11/04/20
Earnings Per Share ttm -1.73
EPS Growth vs. Prev Qtr 31.82%
EPS Growth vs. Prev Year 25.00%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

IMMU Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -132.40%
Return-on-Assets % -51.32%
Profit Margin % -119,063.33
Net Margin % -102.45
Debt/Equity 0.00
Price/Sales 68,810.40
Price/Cash Flow N/A
Price/Book 34.29
Book Value/Share 2.56
Interest Coverage -7.86
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar